Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature

K. Ghasemi Falavarjani, Q. D. Nguyen

Research output: Contribution to journalReview article

282 Scopus citations

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

Original languageEnglish (US)
Pages (from-to)787-794
Number of pages8
JournalEye (Basingstoke)
Volume27
Issue number7
DOIs
StatePublished - May 31 2013

Keywords

  • Aflibercept
  • Anti-vascular endothelial growth factor
  • Bevacizumab
  • Intravitreal injection
  • Ranibizumab
  • Safety

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Fingerprint Dive into the research topics of 'Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature'. Together they form a unique fingerprint.

  • Cite this